Prevalence and correlates of skin self-examination practices among cutaneous malignant melanoma survivors.

Melanoma survivors Skin cancer surveillance Skin self-exam

Journal

Preventive medicine reports
ISSN: 2211-3355
Titre abrégé: Prev Med Rep
Pays: United States
ID NLM: 101643766

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 04 12 2019
revised: 06 03 2020
accepted: 26 04 2020
entrez: 29 5 2020
pubmed: 29 5 2020
medline: 29 5 2020
Statut: epublish

Résumé

Melanoma patients are at elevated risk for recurrence of the primary cancer as well as second primary melanomas. Regular skin self-examination (SSE) is recommended as part of follow-up surveillance. In this study, we examined SSE performance and comprehensiveness as well as knowledge and attitudinal correlates of SSE performance and comprehensiveness. Four hundred forty-one melanoma survivors completed measures of SSE performance as well as knowledge and attitudes about SSE and melanoma. Approximately two-thirds of the sample reported having conducted an SSE in the past two months; the average number of body parts examined was 10.64 (out of 15 maximum). Only 7.5% of the sample checked all 15 body parts. Greater worry about recurrence, fewer barriers to SSE, more planning for when to conduct SSE, and more confidence in the ability to conduct SSE and recognize a suspicious growth were associated with both SSE performance and greater SSE comprehensiveness. Physician influence was positively associated with SSE performance. Survivor education efforts may benefit from reminding survivors to check hard-to-see and sensitive areas, develop a plan for how to ask for assistance in conducting exams, as well as use mirrors to see hard-to-reach areas. Addressing perceived SSE barriers, fostering SSE planning, and improving SSE self-efficacy may be important foci for intervention efforts to enhance SSE performance and comprehensiveness.

Identifiants

pubmed: 32461880
doi: 10.1016/j.pmedr.2020.101110
pii: S2211-3355(20)30070-X
pii: 101110
pmc: PMC7240727
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101110

Subventions

Organisme : NCI NIH HHS
ID : HHSN261201300021C
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA171666
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2020 The Authors.

Références

Contemp Clin Trials. 2019 Aug;83:117-127
pubmed: 31255801
Prev Med. 1994 Mar;23(2):142-51
pubmed: 8047519
Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):971-8
pubmed: 10566551
J Am Acad Dermatol. 2012 Jan;66(1):37-45
pubmed: 21700361
Cancer. 1999 Nov 15;86(10):2014-20
pubmed: 10570426
Psychooncology. 2009 Oct;18(10):1106-15
pubmed: 19142859
Br J Health Psychol. 2008 Sep;13(Pt 3):525-35
pubmed: 17631695
Br J Surg. 2008 Nov;95(11):1401-7
pubmed: 18844268
Psychooncology. 2012 Dec;21(12):1285-91
pubmed: 21780240
Contemp Clin Trials. 2013 May;35(1):159-67
pubmed: 23557730
J Behav Med. 2006 Oct;29(5):419-34
pubmed: 16855870
Melanoma Res. 2016 Feb;26(1):71-6
pubmed: 26426762
BMC Public Health. 2011 Nov 14;11:866
pubmed: 22082038
Oncol Nurs Forum. 2006 May 03;33(3):633-7
pubmed: 16676019
J Natl Cancer Inst. 2005 Feb 2;97(3):195-9
pubmed: 15687362
Subst Use Misuse. 2015;50(10):1249-60
pubmed: 26440754
Ann Behav Med. 2003 Winter;25(1):16-24
pubmed: 12581932
Health Psychol. 2000 Sep;19(5):487-95
pubmed: 11007157
Health Educ Res. 2007 Oct;22(5):630-8
pubmed: 17060349
Health Educ Behav. 1999 Jun;26(3):344-59
pubmed: 10349572
J Natl Cancer Inst. 1996 Jan 3;88(1):17-23
pubmed: 8847720
J Am Acad Dermatol. 2011 Aug;65(2):427-428.e1
pubmed: 21763569
J Am Acad Dermatol. 2008 May;58(5):755-62
pubmed: 18258332
Psychol Health. 2009 Jan;24(1):49-65
pubmed: 20186639
Lancet Oncol. 2005 Aug;6(8):608-21
pubmed: 16054572

Auteurs

Sharon L Manne (SL)

Rutgers Cancer Institute of New Jersey, United States.

Carolyn J Heckman (CJ)

Rutgers Cancer Institute of New Jersey, United States.

Deborah Kashy (D)

Michigan State University, United States.

Carolina Lozada (C)

Rutgers Cancer Institute of New Jersey, United States.

Joseph Gallo (J)

Rutgers Cancer Institute of New Jersey, United States.

Lee Ritterband (L)

University of Virginia, United States.

Elliot J Coups (EJ)

Rutgers Cancer Institute of New Jersey, United States.

Classifications MeSH